Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BerGenBio
Biotech
BerGenBio shifts focus from COVID—to COVID in new strategy
After a phase 2 fail in COVID-19 last year, BerGenBio is shifting its business strategy to focus on, well, still COVID-19.
Annalee Armstrong
May 5, 2022 10:57am
After phase 2 flop, BerGenBio posts new data on COVID prospect
Apr 26, 2022 2:26pm
BerGenBio fails COVID-19 trial, makes post hoc case for program
May 19, 2021 9:00am
BerGenBio posts updated data on trial of elderly AML patients
Jun 14, 2019 9:57am
BerGenBio’s AXL inhibitor clears early efficacy test in NSCLC
Jan 9, 2018 8:37am
EuroBiotech Report: Ogeda, Verona, Calypso and more
Apr 6, 2017 10:41am
